ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18 2023 - 8:12AM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of patients with renal and inflammatory
diseases who have unmet medical needs, announces that Stephen C.
Glover, Co-Founder, Chairman, Chief Executive Officer, and
President, will participate in BIO Partnering @ JPM being held
January 8-12, 2024 in San Francisco.
Details of the events are as follows:
Event: |
BIO
Partnering @ JPM |
Date: |
January 8-12, 2024 |
Location: |
San Francisco Marriott Marquis, 780 Mission St, San Francisco,
CA |
Registration: |
https://bpjw.bio.org/registration |
|
|
During the conference, Mr. Glover will hold one-on-one meetings
with pharmaceutical companies and investors to discuss ZyVersa’s
business and clinical development strategy, recent corporate
achievements, and anticipated milestones. To schedule a
meeting with Mr. Glover, please sign up in the conference portal or
contact Karen Cashmere, Chief Commercial Officer at
kcashmere@zyversa.com.
“2024 is expected to be a pivotal year for ZyVersa as we plan to
initiate a Phase 2a clinical trial with our Cholesterol Efflux
Mediator™ VAR 200 in development to ameliorate renal lipid
accumulation that damages the kidney’s filtration system leading to
kidney dysfunction and disease progression,” said Mr. Glover. “We
look forward to meeting with industry strategics and investors
during J.P. Morgan Week 2024 to discuss the value building
opportunities expected with our VAR 200 program, as well as
development plans for our proprietary Inflammasome ASC Inhibitor IC
100, which is designed to block initiation and perpetuation of
damaging inflammation associated with a multitude of inflammatory
diseases.”
To learn more about ZyVersa and its innovative and
differentiated product pipeline, please visit www.zyversa.com.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes clinical stage Cholesterol Efflux
Mediator™ VAR 200 in development to alleviate damaging
accumulation of cholesterol and lipids in the kidneys’ filtration
system. The lead indication is treatment of rare kidney disease,
focal segmental glomerulosclerosis. VAR 200 has potential to treat
other kidney diseases, including Alport syndrome and diabetic
kidney disease. ZyVersa’s pipeline also includes proprietary
inflammasome ASC inhibitor IC 100 that blocks initiation and
perpetuation of damaging inflammation associated with a multitude
of inflammatory diseases. IC 100 has potential to treat many
different CNS and other inflammatory diseases. For more
information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional financing. A
discussion of these and other factors, including risks and
uncertainties with respect to ZyVersa, is set forth in ZyVersa’s
filings with the Securities and Exchange Commission, including
ZyVersa’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
Corporate and IR ContactKaren CashmereChief
Commercial
Officerkcashmere@zyversa.com 786-251-9641
Media ContactsCasey
McDonaldcmcdonald@tiberend.com 646-577-8520
Dave SchemeliaDschemelia@tiberend.com 609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024